Patent ID: 9284556
Filing Date: 2016-03-15
CPC Classification: A61K,A61P,C12N

Claim Text:
1. A method for the treatment of hepatitis B infection or hepatitis B/hepatitis D co-infection, the method comprising administering to a patient in need of such treatment an antisense oligonucleotide that targets mRNA of the HBV genome encoding the hepatitis B surface antigen (HBsAg) and catalyzes degradation of that mRNA, and at least one pharmaceutically acceptable agent selected from the group consisting of: thymosin α1; interferon β-1a; interferon β-1b; interferon γ-1b; interferon λ1; interferon λ2; interferon λ3; pegylated interferon λ1; pegylated interferon λ2; GS-9620 (4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one); dehydroepiandrosterone; androstenediol; and androstenetriol.